Drug Approval | February 24, 2023
SERDA therapeutics submits IND for wound debridement agent
Clinical studies are expected to start in Q2 2023.
Clinical studies are expected to start in Q2 2023.
Ghostine has served as CEO of Geneva-based Firmenich, the world's largest privately owned perfume and taste company, since 2014.
The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability
Ayurveda is one of the most advanced sciences of its times
A total of 889 M&A deals were announced in the medical devices sector in 2022 worth $93 billion
Becomes the 1st diagnostics company in India to launch BD MAX MDR TB test
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
Cipla has received 8 inspectional observations in Form 483
Canagliflozin and Metformin Hydrochloride Tablets had annual sales of US $49.4 million in the United States
There is a fast resurgence in the transplant activities post COVID
Subscribe To Our Newsletter & Stay Updated
